Product
소개
RemiBridge ELISA For Remicade Biosimilar comparison
Complete kit for the systematic 3-D conformational comparability analysis of
Remicade biosimilar molecule to Infliximab (Remicade trade name)
Infliximab is a chimeric monoclonal antibody against tumor necrosis factor-alpha (TNF-α). TNF-α is a cytokine, or chemical messenger, and a key part of the autoimmune reaction. Infliximab was first approved by the FDA in 1998 for the treatment of Crohn’s disease. It has subsequently been approved for use in treating psoriasis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.
This kit will allow for conformational (Higher-Order Structure) comparison between Remicade Biosimilars and authentic Infliximab.
주문정보
AB000209 RemiBridge ELISA (for Remicade Biosimilar comparison) 1 Kit
관련자료